Welcome to our dedicated page for Lilly Eli & news (Ticker: LLY), a resource for investors and traders seeking the latest updates and insights on Lilly Eli & stock.
Eli Lilly & Co. develops and commercializes medicines across cardiometabolic disease, oncology, immunology, neuroscience and genetic medicine. Company news commonly covers product and pipeline developments for medicines such as Mounjaro, Zepbound, Foundayo, Omvoh, Verzenio, Jaypirca and Taltz, including clinical data, regulatory approvals and treatment-indication updates.
Lilly updates also include operating results, financial guidance, dividends, business development agreements and manufacturing expansion. Recent company communications highlight investment in active pharmaceutical ingredient capacity and genetic medicine production, alongside recurring disclosures about demand for diabetes, obesity, immune-disease and cancer therapies.
Innovent Biologics and Lilly (NYSE: LLY) signed a commercialization agreement for Verzenios (abemaciclib) in mainland China. Innovent gains sole commercialization rights, handling importation, marketing, distribution and promotion, while Lilly, as Marketing Authorization Holder, continues manufacturing, supply and development. Verzenios is NRDL-listed across early and advanced breast cancer indications.
Lilly (NYSE: LLY) received a positive CHMP opinion recommending Jaypirca (pirtobrutinib) for adults with chronic lymphocytic leukemia (CLL) across all lines of therapy, regardless of prior BTK inhibitor use. The opinion is based on Phase 3 BRUIN CLL-313 and BRUIN CLL-314 trials.
The application now goes to the European Commission, with a decision expected in one to two months. Lilly has also submitted these data to the U.S. FDA, with a CLL decision anticipated in the second half of 2026.
Eli Lilly (NYSE: LLY) outlined how Medicare Part D patients can access its obesity medicines Foundayo (orforglipron) and Zepbound (tirzepatide) through the new Medicare GLP-1 Bridge program starting July 1, 2026.
Eligible Part D patients who meet CMS clinical criteria and obtain prior authorization may receive either drug for $50 per month through December 31, 2027. Lilly estimates about 20 million Medicare patients may meet clinical criteria. Phase 3 data showed average weight loss of 13% with Foundayo and 14.1% with Zepbound in adults 65+ without type 2 diabetes, with safety profiles generally consistent with other ages.
Eli Lilly (NYSE: LLY) has completed its acquisition of Centessa Pharmaceuticals, a clinical-stage company focused on orexin receptor 2 agonists for narcolepsy and other sleep-wake disorders. Lilly plans to advance Centessa's clinical portfolio to address unmet needs in conditions driven by disrupted sleep and wakefulness.
Eli Lilly (NYSE: LLY) announced its third-quarter 2026 dividend. The board declared a cash dividend of $1.73 per share on outstanding common stock.
The dividend will be paid on September 10, 2026, to shareholders of record as of August 14, 2026.
Lilly (NYSE: LLY) reported Phase 3 BRUIN CLL-322 results in relapsed or refractory CLL/SLL. Adding Jaypirca (pirtobrutinib) to venetoclax plus rituximab cut the risk of disease progression or death by 45% (HR=0.55; p=0.0001).
Among 639 patients (79.8% BTK-pretreated), median PFS was not reached with the triple regimen versus 39.7 months for control. Time to next treatment favored Jaypirca (HR=0.50). Overall survival data are immature. Safety was broadly consistent with known profiles, with similar Grade ≥3 AE and discontinuation rates.
Lilly (NYSE: LLY) reported initial Phase 1 AJX-101 data for its first-in-class type II JAK2 inhibitor AJ1-11095 in previously treated myelofibrosis, to be presented at the 2026 EHA Annual Meeting.
Results show high rates of spleen volume reduction, symptom improvement, VAF decreases, and a generally manageable safety profile.
Eli Lilly (NYSE: LLY) launched a national Watch This campaign with Shaquille O'Neal, highlighting that his long-standing symptoms were moderate obstructive sleep apnea (OSA) treated with Zepbound (tirzepatide).
Zepbound is the first and only prescription medicine for moderate-to-severe OSA in adults with obesity, used with diet and exercise, and showed significant 52-week reductions in breathing interruptions and symptom remission in clinical studies.
Eli Lilly (NYSE: LLY) received FDA approval for an every-eight-week maintenance dosing regimen of EBGLYSS (lebrikizumab-lbkz) for adults and adolescents (≥12 years, ≥40 kg) with moderate-to-severe atopic dermatitis.
The single 250 mg/2 mL subcutaneous injection allows as few as six maintenance doses per year without required prescription topicals from treatment start, supported by Phase 3 ADjoin extension data and exposure-response modeling.
Convatec and the Lilly Foundation, supported by Eli Lilly (NYSE:LLY), committed c.$5 million to Partners In Health (PIH) to strengthen care for non‑communicable and chronic conditions in resource‑limited settings.
The funding supports community health workers, training, diagnosis, referral pathways, and academic collaboration in countries including Rwanda, Peru, Malawi and Sierra Leone, honoring former Convatec CEO Karim Bitar’s legacy.